Next Steps After Phase III BEACON CRC Trial in mCRC
January 19th 2019Pashtoon M. Kasi, MD, MBBS, MS, discusses how the triplet regimen of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab, will impact the treatment landscape for patients with metastatic colorectal cancer.